Literature DB >> 16328320

Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy.

Péter Doró1, Ria Benko, Edit Kosik, Mária Matuz, Katalin Tóth, Gyöngyvér Soós.   

Abstract

OBJECTIVE: To describe the quantitative and qualitative changes in the utilization of oral antihyperglycemic drugs (OAHDs) between 1998 and 2004 and to analyze patients' adherence to OAHD therapy.
METHODS: We conducted a retrospective analysis of the electronic database of the Hungarian National Health Fund Administration for the years 1998 through 2004. All 912,620 prescriptions for OAHDs dispensed for the 38,855 patients in Csongrád County (430,000 inhabitants) were retrieved and analyzed according to the ATC/DDD (World Health Organization) methodology. Nonadherence was set as medication possession ratio <80%.
RESULTS: The number of patients using OAHDs significantly increased (P<0.001); the yearly prevalence of 2.88% in 1998 increased to 4.32% in 2004. The overall consumption of OAHDs increased by 76%, from 20.85 defined daily doses per 1,000 inhabitants per day (DDD/TID) in 1998 to 36.83 DDD/TID in 2004. While in 1998 glibenclamide was the most often prescribed agent, received by 61.7% of patients, its share dropped to 16.1% in 2004, and metformin became the leading agent prescribed for 43.0% of patients. During the study period, the adherence rate varied between 47.9% and 49.2%. Women had a significantly better (P<0.001) adherence rate than men, 51.3% vs. 45.5%. The adherence rate peaked in patients between 60 and 79 years and was lowest in patients in their 30s.
CONCLUSIONS: The utilization pattern of OAHDs considerably changed, but there were no significant changes in patients' adherence. The significant increase in the utilization of OAHDs is not the result of increased adherence but of increased patient number.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328320     DOI: 10.1007/s00228-005-0031-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  The association between diabetes metabolic control and drug adherence in an indigent population.

Authors:  Joel M Schectman; Mohan M Nadkarni; John D Voss
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

2.  Effect of number of medications on cardiovascular therapy adherence.

Authors:  Stephen J Shalansky; Adrian R Levy
Journal:  Ann Pharmacother       Date:  2002-10       Impact factor: 3.154

Review 3.  Comparison of dose standard units for drug utilisation studies.

Authors:  J Merlo; A Wessling; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management--2000 update.

Authors: 
Journal:  Endocr Pract       Date:  2000 Jan-Feb       Impact factor: 3.443

5.  Polypharmacy and medication adherence in patients with type 2 diabetes.

Authors:  Richard W Grant; Nicole G Devita; Daniel E Singer; James B Meigs
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

Review 6.  A systematic review of adherence with medications for diabetes.

Authors:  Joyce A Cramer
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

7.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Sarah Wild; Gojka Roglic; Anders Green; Richard Sicree; Hilary King
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

8.  Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey.

Authors:  G Charpentier; N Genès; L Vaur; J Amar; P Clerson; J P Cambou; P Guéret
Journal:  Diabetes Metab       Date:  2003-04       Impact factor: 6.041

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.

Authors:  Rajesh Balkrishnan; Rukmini Rajagopalan; Fabian T Camacho; Sally A Huston; Frederick T Murray; Roger T Anderson
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

View more
  13 in total

Review 1.  [Use of prescription drugs in Spain and Europe].

Authors:  Juan Simó Miñana
Journal:  Aten Primaria       Date:  2011-10-22       Impact factor: 1.137

2.  How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus.

Authors:  Thomas Wilke; Antje Groth; Sabrina Mueller; Dallas Reese; Roland Linder; Susanne Ahrens; Frank Verheyen
Journal:  Eur J Health Econ       Date:  2012-07-20

3.  Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial.

Authors:  Stephanie R Land; Walter M Cronin; D Lawrence Wickerham; Joseph P Costantino; Nicholas J Christian; William M P Klein; Patricia A Ganz
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-23

4.  Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants - A Retrospective Cohort Study in Health Insurance Claims Data.

Authors:  Lucas Wirbka; Walter Emil Haefeli; Andreas Daniel Meid
Journal:  Patient Prefer Adherence       Date:  2021-09-24       Impact factor: 2.711

5.  Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?

Authors:  Thomas Grimmsmann; Wolfgang Himmel
Journal:  Eur J Clin Pharmacol       Date:  2011-03-10       Impact factor: 2.953

6.  Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies.

Authors:  Jason C Hsu; Dennis Ross-Degnan; Anita K Wagner; Ching-Lan Cheng; Yea-Huei Kao Yang; Fang Zhang; Christine Y Lu
Journal:  J Pharm Policy Pract       Date:  2015-04-25

7.  Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study.

Authors:  Amir Sarayani; Arash Rashidian; Kheirollah Gholami
Journal:  BMJ Open       Date:  2014-10-16       Impact factor: 2.692

8.  Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database.

Authors:  Isabelle Arnet; Melanie Greenland; Matthew W Knuiman; Jamie M Rankin; Joe Hung; Lee Nedkoff; Tom G Briffa; Frank M Sanfilippo
Journal:  Clin Epidemiol       Date:  2018-09-06       Impact factor: 4.790

9.  Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.

Authors:  György Jermendy; Diana Erdesz; Laszlo Nagy; Don Yin; Hemant Phatak; Sudeep Karve; Samuel Engel; Rajesh Balkrishnan
Journal:  Health Qual Life Outcomes       Date:  2008-10-31       Impact factor: 3.186

10.  A method for calculating adherence to polypharmacy from dispensing data records.

Authors:  Isabelle Arnet; Ivo Abraham; Markus Messerli; Kurt E Hersberger
Journal:  Int J Clin Pharm       Date:  2013-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.